{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-100918","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.188107+00:00","generated_at":"2026-05-17T22:18:19.429078+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ultragenyx fully enrolls Phase 3 Aspire study (129 patients) for GTX-102 in Angelman Syndrome","bullets":["Phase 3 Aspire study fully enrolled with ~129 patients ages 4-17 with maternal UBE3A deletion.","Participants randomized 1:1 to GTX-102 intrathecal injection or sham comparator for 48 weeks; sham can cross over after Week 48.","Primary endpoint: Bayley-4 cognitive raw score improvement; key secondary: MDRI across five domains.","Study completion expected H2 2026; company plans to move to topline data and regulatory submission."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-100918","json":"https://secwatch.observer/filing/0000950170-25-100918.json","markdown":"https://secwatch.observer/filing/0000950170-25-100918.md","text":"https://secwatch.observer/filing/0000950170-25-100918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025100918/0000950170-25-100918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025100918/rare-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:18:19.429078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}